6505--VA San Diego Lymphoseek IDIQ
Veterans Affairs · 262-NETWORK CONTRACT OFFICE 22 (36C262)
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation 36C26226Q0421 in this department, oldest first.
- Feb 26, 2026 · this noticeSpecial Notice
- Mar 18, 2026Award NoticeCARDINAL HEALTH 414, LLC · $259KOpen
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Answer the notice: this is when the requirement can still be shaped.
- Contact the contracting officer named on the notice.
- Check who won similar work; they are the likely bidders.
What the notice says
Special Notice Page 3 of 3 NOTICE OF INTENT TO SOLE SOURCE This notice is being published in accordance with Federal Acquisition Regulation (FAR) Subpart 5.101 requiring dissemination of information for proposed contract actions. This is a notice of intent to award a sole source contract and is not a request for competitive quotes/proposals. The Department of Veterans Affairs, Network Contracting Office (NCO) 22, located at 4811 Airport Plaza Drive, Long Beach, CA is issuing this Notice of Intent (NOI) to inform industry contractors of the Government s intent to execute a Sole Source Delivery … (show all)
Order under FAR Part 6 in conjunction with FAR part 12, specifically FAR Part 6.103-1, only one responsible source and no other supplies or services will satisfy agency requirements. The North American Industry Classification System (NAICS) for this requirement is 325412, Pharmaceutical Preparation Manufacturing. The Federal Supply Class (FSC) is 6505, Drugs and Biologicals. The Small Business Administration (SBA) size standard for this sector is 1,300 Employees. The intended contractor is Cardinal Health 414, LLC located at 7000 Cardinal Place, Dublin, OH 43017. Place of Performance is the VA San Diego Healthcare System located at 3350 La Jolla Village Drive, San Diego, CA 92161. Period of performance is base plus option four years with dates specified below. VA San Diego Nuclear Medicine Service intends to purchase Lymphoseek in quantities listed below: Period of Performance Description Qty Unit Base (4/1/26 - 3/31/27) 99mTC Tilmanocept (Lymphoseek®) UD 4 syringes 25 EA Option year 1 (4/1/27 - 3/31/28) 99mTC Tilmanocept (Lymphoseek®) UD 4 syringes 25 EA Option year 2 (4/1/28 - 3/31/29) 99mTC Tilmanocept (Lymphoseek®) UD 4 syringes 25 EA Option year 3 (4/1/29 - 3/31/30) 99mTC Tilmanocept (Lymphoseek®) UD 4 syringes 25 EA Option year 4 (4/1/30 - 3/31/31) 99mTC Tilmanocept (Lymphoseek®) UD 4 syringes 25 EA VA San Diego Healthcare System Nuclear Medicine Service requires Lymphoseek to be used for the localization of lymph nodes prior to definitive surgery and treatment of patients with melanoma or other cancers receiving services. This notice of intent is neither a formal solicitation nor a request for competitive proposals. No solicitation document is available and telephone requests will not be honored. No award will be made on the basis of unsolicited quotations or offers received in response to this notice. Any response to this notice must show clear and compelling evidence that the responding company can provide the same items/services, and that competition will be advantageous to the Government. The intent of this synopsis is for informational purposes only. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. A determination by the Government not to compete this action based on this notice is solely within the discretion of the Government. All inquiries and concerns must be addressed in writing via e-mail to Hestia Sim, Hestia.Sim@va.gov with RESPONSE TO INTENT TO SOLE SOURCE Lymphoseek in the subject line. All interested parties who are responsible, certified, and capable may identify their interest and may submit a capabilities statement no later than 10:00 AM Pacific Local Time March 5, 2026, to the above-mentioned point of contact. The interested parties bear full responsibility to ensure complete transmission and timely receipt. The Department of Veterans Affairs will NOT be responsible for any costs incurred by interested parties in responding to this notice of intent.
Who won similar work
27 award notices on SAM.gov in the last 24 months. Matched by: Same office (262-NETWORK CONTRACT OFFICE 22 (36C262)), same product/service code (PSC) 6505 and NAICS 325412.
Single-winner award sizes (27): middle half $583K to $3.6M, median $1.8M; range $53K to $37.3M.
| Winner | Awards | Value | Last |
|---|---|---|---|
| EXELAN PHARMACEUTICALS INC | 9 | $42.2M | Jan 28, 2026 |
| RLS (USA) INC. | 4 | $9.6M | Mar 5, 2026 |
| CARDINAL HEALTH 414, LLC · $CAH · $254.2B | 3 | $670K | Oct 1, 2026 |
| Novartis Pharmaceuticals Corporation | 2 | $8.9M | Jan 8, 2026 |
| ADVANCED ACCELERATOR APPLICATIONS USA INC | 2 | $6.4M | Dec 16, 2024 |
| BOSTON SCIENTIFIC CORP · $BSX · $21.0B | 2 | $1.4M | Dec 23, 2025 |
| PROGENICS PHARMACEUTICALS INC | 2 | $1.2M | Aug 21, 2025 |
| SIRTEX MEDICAL INC | 1 | $37.3M | Nov 12, 2025 |
| TELIX PHARMACEUTICALS US INC | 1 | $496K | Apr 22, 2026 |
| Bristol-Myers Squibb Company | 1 | $364K | Jun 30, 2026 |
Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.
- $CAH reported $254.2B revenue (fiscal year ending Jun 30, 2026). The median single-winner award in these 27 past awards, $1.8M, is under 0.1% of that. SEC filing
- $BSX reported $21.0B revenue (12 months to Jun 30, 2026). The median single-winner award in these 27 past awards, $1.8M, is under 0.1% of that. SEC filing
One award's total value against one year of revenue; many awards are paid over several years.
- Oct 1, 2026CARDINAL HEALTH 414, LLC$53K6505--VALL Iodine Isotope IDIQMateriality: <0.01% of $CAH revenue (Low) SEC
- Jun 30, 2026Bristol-Myers Squibb Company$364K6505--Emergency BreyanziMateriality: <0.01% of $BMY revenue (Low) SEC
- Apr 22, 2026TELIX PHARMACEUTICALS US INC$496K6505--VA San Diego PSMANo listed company matched (Materiality N/A)
- Mar 5, 2026RLS (USA) INC.$752K6505--VA Tucson Radiopharmaceuticals Base DONo listed company matched (Materiality N/A)
- Mar 5, 2026RLS (USA) INC.$1.6M6505--VA Phoenix Radiopharmaceuticals Base DONo listed company matched (Materiality N/A)
- Feb 24, 2026RLS (USA) INC.$7.0M6505--VA Phoenix and Tucson Radiopharmaceuticals IDIQNo listed company matched (Materiality N/A)
- Jan 28, 2026EXELAN PHARMACEUTICALS INC$3.3M6505--VA San Diego Lenalidomide DONo listed company matched (Materiality N/A)
- Jan 14, 2026EXELAN PHARMACEUTICALS INC$3.7M6505--VA Long Beach Lenalidomide DONo listed company matched (Materiality N/A)
- Jan 14, 2026EXELAN PHARMACEUTICALS INC$2.1M6505--VA Albuquerque Lenalidomide DONo listed company matched (Materiality N/A)
- Jan 14, 2026EXELAN PHARMACEUTICALS INC$2.1M6505--VA Loma Linda Lenalidomide DONo listed company matched (Materiality N/A)
Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.
Competitive landscape
For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 1 of these past winners lobbied Veterans Affairs, Dept of (VA) since 2024 (10 filings)
- 1 of their lobbyists list a past Veterans Affairs, Dept of (VA) job
- $63K from their corporate PACs since 2024 to members of House Committee on Appropriations, House Committee on Veterans' Affairs, Senate Committee on Appropriations, Senate Committee on Veterans' Affairs
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 3 bills named on the past winners' lobbying filings
- 25 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 2 of the past winners are listed companies
- 5 insider buys and 7 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.